cervical cancer
Conditions
Interventions
None listed
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patient age range between 18 - 70 years old; 2. Pathological diagnosis included clear cervical squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma; 3. Pelvic lymph node metastasis was confirmed histologically, the tumor was longer than 2cm, and the number was limited to 3 lesions. doctors believe that the metastatic lymph node is adaptive for interstitial brachytherapy; 4. These patients were classified into stage IIIC, and IVA by FIGO stage and had no surgery; 5. Those patients are willing to receive invasive interstitial brachytherapy; 6. ECOG:0-1; 7. Experimental examination should be carried out within 14 days before enrollment, including bone marrow, liver, and kidney function testing: (1) Leukocyte was greater than 3.5 x 10^9 / L; platelet was greater than 100 x 10^9 / L; hemoglobin-vb was greater than 100g / L (acceptable using blood transfusion or other methods); (2) Liver function is in the normal range: gluthyltransferase and glutgrass transaminase were below 1.5 times the upper limit, alkaline phosphatase was below 2.5 times the upper limit, and bilirubin was below the upper normal value; (3)Renal function is within the normal range: creatinine clearance (CCr) was greater than 60 ml/min. The calculation formula is as follows, CCr= (140-age) x Weight (kg) / [72 Scr x (mg/dl)] or CCr= [(140-age)*Weight (kg)] / [0.818 Scr *(umol/L)], Prothrombin international ratio (INR) was less than or equal to 1.5; 8. Fertile women must agree to take effective contraception throughout the treatment study period; 9. Patients must sign an informed consent form before enrollment.
Exclusion criteria
Exclusion criteria: 1. Other pathological types of cervical malignant tumors, such as undifferentiated cancer, neuroendocrine cancer, sarcoma; 2. Severe bleeding or active bleeding performance; 3. The patient has accepted neoadjuvant chemotherapy; 4. The patient has a history of pelvic or abdominal radiotherapy; 5. Allergy or contraindications to the drugs needed to be used in this study; 6. The patient was combined with the following severely active concurrent diseases: such as unstable angina in the past 6 months, congestive heart failure requiring hospitalization; myocardial infarction in the last 6 months; acute bacterial or fungal infection requiring intravenous antibiotics, antifungal treatment; deteriorating chronic obstructive pulmonary disease or other respiratory diseases requiring hospitalization or obstructing the study; liver dysfunction leads to jaundice or coagulation disorders; 7. The patient has blood coagulation dysfunction; 8. Uncontrollable hypertension and diabetes; 9. The patient was combined with other malignant tumors; 10. The patient was combined with AIDS, and other immunocompromised patients, such as organ transplantation, and long-term use of glucocorticoids; 11. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ;; | — |
Countries
China
Contacts
Public ContactZhenhua Zhang
Affiliated Hospital of Southwest Medical University
Outcome results
None listed